Rheonix gets FDA nod for STI test, workstation

By LabPulse.com staff writers

January 12, 2022 -- Rheonix announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its automated workstation software and molecular test for sexually transmitted infections (STIs).

The Encompass MDx workstation enables scalable, multiplexed sample-to-answer detection, simplifying laboratory workflows.

The Rheonix STI triplex assay and male urine collection kit is approved for simultaneous detection and differentiation of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.

Rhoenix gets emergency clearance for COVID-19 assay
The U.S. Food and Drug Administration has granted molecular testing company Rhoenix emergency use authorization for a fully automated test to detect the...

Copyright © 2022 LabPulse.com

Last Updated ls 1/12/2022 3:18:18 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current